Oppenheimer Reiterates Outperform on Catalyst Pharmaceuticals, Maintains $29 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell reiterates an Outperform rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and maintains a $29 price target.
March 27, 2024 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Leland Gershell reaffirmed an Outperform rating on Catalyst Pharmaceuticals, with a $29 price target.
The reaffirmation of an Outperform rating and a $29 price target by a reputable analyst suggests a positive outlook for Catalyst Pharmaceuticals. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100